

Name	: Mr. SRIDHAR B	REG/LAB NO.	: 23010195 / 1142
AGE/SEX	: 32 Yrs / Male	DATE OF COLLECTION	: 28-01-2023 at 09:48 AM
REFERRED BY	:	DATE OF REPORT	: 30-01-2023 at 11:01 AM
REF CENTER	: MEDIWHEEL		

TEST PARAMETER	RESULT	REFERENCE RANGE
BLOOD GROUP	"B"	
RH TYPE	POSITIVE	
<u>COMPLETE BLOOD COUNT(CBC)</u>		
HAEMOGLOBIN	18.4 gm/dl	14 - 18 gm/dl
TOTAL COUNT	6600 cells/cumm	4000 - 11000 cells/cumm
<u>DIFFERENTIAL COUNT</u>		
NEUTROPHILS	57 %	40 - 70 %
LYMPHOCYTES	33 %	20 - 45 %
EOSINOPHILS	04 %	2 - 8 %
MONOCYTES	06 %	1 - 6 %
BASOPHILS	00 %	0 - 1 %
PLATELET COUNT	2.0 Lakhs/cumm	1.5 - 4.5 Lakhs/cumm
R.B.C COUNT	5.6 mill/cumm	4.5 - 6.2 mill/cumm
PACKED CELL VOLUME (PCV)	56 %	37 - 47 %
M.C.V	100 fl	80 - 98 fl
M.C.H	33 pg	26 - 34 pg
M.C.H.C	32 %	31 - 38 %
FASTING BLOOD SUGAR	97 mg/dl	60 - 110 mg/dl

COMMENTS :

80 - 99 mg/dL : Normal, 100 - 125 mg/dL : Impaired Fasting Glucose (Pre-Diabetes), >126 mg/ dL : Diabetes.
reference intervals for FBS from ADA RECOMMENDATION 2015.

A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.

Impaired fasting glucose (IFG) : Fasting glucose repeatedly is at upper limit, family history or abnormal lipid profile.

Advised : HbA1c and clinical correlation.

NOTE :

In absence of pregnancy, IGT and IFG are risk factors for future DM and cardiovascular disease ; they are not clinical entities.

A person's blood glucose levels normally move up and down depending on meals , Exercise, sickness, and stress.



Name	: Mr. SRIDHAR B	REG/LAB NO.	: 23010195 / 1142
AGE/SEX	: 32 Yrs / Male	DATE OF COLLECTION	: 28-01-2023 at 09:48 AM
REFERRED BY	:	DATE OF REPORT	: 30-01-2023 at 11:01 AM
REF CENTER	: MEDIWHEEL		

TEST PARAMETER	RESULT	REFERENCE RANGE
HbA1c (GLYCOSYLATED Hb) <i>HPLC</i>	4.9 %	Normal: <5.7 Pre-Diabetes: 5.7-6.4 Diabetes: 6.5

MEAN BLOOD GLUCOSE 89.2
Calculated

Degree of Control	HbA1c	MBG
Normal	< 6.0 %	61-124 mg/dl
Good Control	6.0-7.0 %	124-156 mg/dl
Fair Control	7.0-8.0 %	158-188 mg/dl
Poor Control	> 8.0 %	>188 mg/dl

Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c.
- Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments:

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations. ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

LIPID PROFILE TEST (LPT)

TOTAL CHOLESTEROL	198 mg/dl	up to 200 mg/dl
TRIGLYCERIDES	391 mg/dl	up to 200 mg/dl Special condition: Borderline high risk : 200 - 400 mg/dL Elevated : > 400 mg/dL
HDL CHOLESTEROL - DIRECT	37 mg/dl	35 - 55 mg/dl
LDL CHOLESTEROL - DIRECT	82.8 mg/dl	up to 150 mg/dl
VLDL CHOLESTEROL	78.2 mg/dl	0 - 60 mg/dl
TC/HDL	5.4	
LDL/HDL	2.2	

Remarks: Values rechecked kindly correlate clinically



Name : **Mr. SRIDHAR B**
 AGE/SEX : 32 Yrs / Male
 REFERRED BY :
 REF CENTER : MEDIWHEEL

REG/LAB NO. : 23010195 / 1142
 DATE OF COLLECTION : 28-01-2023 at 09:48 AM
 DATE OF REPORT : 30-01-2023 at 11:01 AM



TEST PARAMETER	RESULT	REFERENCE RANGE
----------------	--------	-----------------

LIVER FUNCTION TEST (LFT)

TOTAL BILIRUBIN	1.5 mg/dl	0 - 1 mg/dl
DIRECT BILIRUBIN	0.6 mg/dl	0 - 0.25 mg/dl
INDIRECT BILIRUBIN	0.9 mg/dl	0 - 0.75 mg/dl
TOTAL PROTEIN	5.0 g/dl	6 - 8.5 g/dl
SERUM ALBUMIN	4.6 g/dl	3.5 - 5.2 g/dl
SERUM GLOBULIN	0.4 g/dL	2.3 - 3.5 g/dL
A/G RATIO	11.5	1 - 1.5
ASPARATE AMINOTRANSFERASE (SGOT/AST)	43 U/L	up to 40 U/L
ALANINE AMINOTRANSFERASE (SGPT/ALT)	54 U/L	up to 40 U/L
ALKALINE PHOSPHATASE	114 IU/L	25 - 147 IU/L

Remarks: Values rechecked kindly correlate clinically

POST PRANDIAL BLOOD SUGAR	109 mg/dl	70 - 140 mg/dl
---------------------------	-----------	----------------

RENAL FUNCTION TEST (RFT)

BLOOD UREA	19 mg/dL	11 - 45 mg/dL
SERUM URIC ACID	6.9 mg/dL	4.5 - 8.1 mg/dL
SERUM CREATININE	0.8 mg/dL	0.6 - 1.4 mg/dL



Name	: Mr. SRIDHAR B	REG/LAB NO.	: 23010195 / 1142
AGE/SEX	: 32 Yrs / Male	DATE OF COLLECTION	: 28-01-2023 at 09:48 AM
REFERRED BY	:	DATE OF REPORT	: 30-01-2023 at 11:01 AM
REF CENTER	: MEDIWHEEL		



TEST PARAMETER	RESULT	REFERENCE RANGE
<u>THYROID PROFILE (T3, T4, TSH)</u>		
TOTAL TRIIODOTHYRONINE (T3) <small>CLIA</small>	1.20 ng/mL	0.60-1.81 1st Trimester :0.71 - 1.75 2nd Trimester :0.91 - 1.95 3rd Trimester :1.04 - 1.82
TOTAL THYROXINE (T4) <small>CLIA</small>	8.21 µg/dL	4.5-10.9 1st Trimester :6.5 - 10.1 2nd Trimester :7.5 - 10.03 3rd Trimester :6.3 - 9.7
THYROID STIMULATING HORMONE (TSH) <small>CLIA</small>	3.893 µIU/ml	0.35-5.5 1st Trimester :0.1 - 2.5 2nd Trimester :0.2 - 3.0 3rd Trimester :0.3 - 3.0

Note:

1.TSH levels are subject to circadian variation, reaching peak levels between 2 – 4 a.m. and at a minimum between 6-10 p.m. The variation is of the order of 50% hence time of the day has influence on the measured serum TSH concentrations.

2.Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.

3.Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

Clinical Use:

Primary Hypothyroidism, Hyperthyroidism, Hypothalamic – Pituitary hypothyroidism, Inappropriate TSH secretion, Non thyroidal illness, Autoimmune thyroid disease, Pregnancy ,associated thyroid disorders, Thyroid dysfunction in infancy and early childhood

ESR	04 mm/hr	0 - 20 mm/hr
-----	----------	--------------

Interpretation:

ESR is non specific marker of inflammatory process. Its main clinical utility is in monitoring the course or response to treatment of various acute and chronic disorders like hematologic diseases, malignancy, collagen vascular disorders and renal diseases.



Name	: Mr. SRIDHAR B	REG/LAB NO.	: 23010195 / 1142
AGE/SEX	: 32 Yrs / Male	DATE OF COLLECTION	: 28-01-2023 at 09:48 AM
REFERRED BY	:	DATE OF REPORT	: 30-01-2023 at 11:01 AM
REF CENTER	: MEDIWHEEL		

TEST PARAMETER	RESULT	REFERENCE RANGE
----------------	--------	-----------------

COMPLETE URINE ANALYSIS

PHYSICAL CHARACTERS

COLOUR	PALE YELLOW	PALE YELLOW
APPEARANCE	CLEAR	CLEAR
SPECIFIC GRAVITY	1.010	1.005-1.030
pH	6.0	4.5-7.0

CHEMICAL CONSTITUENTS

ALBUMIN	PRESENT (+)	ABSENT
SUGAR	NIL	ABSENT
BILE SALTS	ABSENT	ABSENT
BILE PIGMENTS	ABSENT	ABSENT
KETONE BODIES	ABSENT	ABSENT

MICROSCOPY

PUS CELLS	2 - 3 /hpf	4-6
R.B.C	NIL	0-4
EPITHELIAL CELLS	1 - 2 /hpf	0-2
CASTS	ABSENT	ABSENT
CRYSTALS	ABSENT	ABSENT
FASTING URINE SUGAR	NIL	NIL
POST PRANDIAL URINE SUGAR (PPUS)	NIL	NIL

STOOL ANALYSIS

PHYSICAL EXAMINATION

CONSISTANCY	SEMI SOLID
COLOUR	BROWNISH
MUCUS	ABSENT
REDUCING SUGAR	ABSENT

MICROSCOPIC EXAMINATION

OVA	NIL
CYST	NIL
PUS CELLS	1-2 /hpf
RBC	NIL



Name	: Mr. SRIDHAR B	REG/LAB NO.	: 23010195 / 1142
AGE/SEX	: 32 Yrs / Male	DATE OF COLLECTION	: 28-01-2023 at 09:48 AM
REFERRED BY	:	DATE OF REPORT	: 30-01-2023 at 11:01 AM
REF CENTER	: MEDIWHEEL		

TEST PARAMETER	RESULT	REFERENCE RANGE
P.S.A	0.50 ng/ml	0 - 4.0

Interpretation

Prostate specific antigen (PSA) is prostate tissue specific, expressed by both normal and neoplastic prostate tissue. PSA total is the collective measurement of its three forms in serum, two forms are complexed to protease inhibitors- alpha 2 macroglobulin and alpha 2 anti-chymotrypsin and third form is not complexed to a protease inhibitor, hence termed free PSA. TPSA =Complex PSA+FPSA.

Use:

Monitoring patients with history of Prostate cancer as an early indicator of recurrence and response to treatment. Prostate cancer screening: Patients with PSA levels >10 ng/mL have >50% probability of prostate cancer.

Increased in:

Prostate diseases: Cancer, Prostatitis, benign prostatic hyperplasia, prostate ischemia, acute urinary retention. Manipulations such as Prostatic massage, cystoscopy, needle biopsy, Transurethral resection, digital rectal examination, indwelling catheter, vigorous bicycle exercise. Physiological fluctuations

Decreased in:


Castration, Antiandrogen drugs, Radiation therapy, Prostatectomy Limitation: It is recommended to use same assay method for long term monitoring. Care should be taken in interpreting results from patients taking drugs such as Buserelin, Finasteride and Flutamide which are known to decrease PSA levels

Dispatched by: Somashekhar h c

**** End of Report ****

Printed by: Somashekhar h c on 30-01-2023 at 11:03 AM

Lab Technician



Dr. Sowmya T.M
DNB ,PDF
Consultant Pathologist



Mediclu Diagnostics & Speciality Centre

Patient Details

Date: 28-Jan-23

Time: 12:59:20

Name: MR SRIDHAR ID: 258741536

Age: 34 y

Sex: M

Height: 171 cms

Weight: 90 Kgs

Interpretation

- Target heart rate achieved 87%.
- Average effort tolerance, Normal HR & BP response.
- No significant ST-T changes during exercise and recovery.
- No angina / Arrhythmias.

IMPRESSION:

- TMT NEGATIVE FOR INDUCIBLE ISCHEMIA.

To correlate clinically.

Ref Doctor: MEDIWHEEL

Doctor: DR. LOKESH KM

(Summary Report edited by user)

Mediclu Diagnostics & Speciality Centre

Patient Details **Date:** 28-Jan-23 **Time:** 12:59:20
Name: MR SRIDHAR **ID:** 258741536
Age: 34 y **Sex:** M **Height:** 171 cms **Weight:** 90 Kgs

Clinical History:

Medications:

Test Details

Protocol: Bruce **Pr.MHR:** 186 bpm **THR:** 167 (90 % of Pr.MHR) bpm
Total Exec. Time: 9 m 7 s **Max. HR:** 161 (87% of Pr.MHR)bpm **Max. Mets:** 13.50
Max. BP: 144 / 99 mmHg **Max. BP x HR:** 23184 mmHg/min **Min. BP x HR:** 7425 mmHg/min
Test Termination Criteria:

Protocol Details

Stage Name	Stage Time (min : sec)	Mets	Speed (mph)	Grade (%)	Heart Rate (bpm)	Max. BP (mm/Hg)	Max. ST Level (mm)	Max. ST Slope (mV/s)
Supine	0 : 16	1.0	0	0	75	144 / 99	-0.64 aVR	1.77 V3
Standing	0 : 14	1.0	0	0	87	144 / 99	-0.64 aVR	1.77 V2
Hyperventilation	0 : 12	1.0	0	0	86	144 / 99	-0.64 aVR	1.77 V2
1	3 : 0	4.6	1.7	10	124	144 / 99	-1.91 aVR	5.66 V3
2	3 : 0	7.0	2.5	12	136	144 / 99	-1.91 aVR	5.66 V2
3	3 : 0	10.2	3.4	14	161	144 / 99	-2.34 III	5.66 V2
Peak Ex	0 : 7	13.5	4.2	16	158	144 / 99	-1.70 aVR	5.66 V2
Recovery(1)	1 : 0	1.8	1	0	118	144 / 99	-2.34 aVR	5.66 V2
Recovery(2)	1 : 0	1.0	0	0	103	144 / 99	-1.91 aVR	5.66 V2
Recovery(3)	1 : 0	1.0	0	0	106	144 / 99	-0.85 aVR	4.95 V3
Recovery(4)	1 : 0	1.0	0	0	91	144 / 99	-0.64 aVR	2.83 V3
Recovery(5)	1 : 0	1.0	0	0	96	144 / 99	-0.64 aVR	1.77 V2
Recovery(6)	0 : 2	1.0	0	0	102	144 / 99	-0.42 aVR	1.42 V2


HR x Stage



BP x Stage



Mets x Stage



NAME:	Mr. SRIDHAR	DATE:	28-01-2023
AGE:	34 YEARS	ID. NO:	200877
GENDER:	MALE	REFERRED BY:	OLYMPUS DIAGNOSTICS

X-RAY REPORT- CHEST (PA VIEW)

OBSERVATIONS:

The lung fields are clear bilaterally.

CP angles are clear.

Both the hila appear normal.

Cardiac diameter is within normal limits.

Trachea is midline.

Visible bony thoracic cage is normal.

Adjacent soft tissues appear normal.

IMPRESSION:

- **No significant abnormality in the visualized lung fields.**



Dr. MOHAN S. MDRD
Consultant radiologist

NAME:	Mr. SRIDHAR	DATE:	28-01-2023
AGE:	34 YEARS	ID. NO:	200877
GENDER:	MALE	REFERRED BY:	OLYMPUS DIAGNOSTICS

USG REPORT - ABDOMEN AND PELVIS

OBSERVATION:

LIVER:

Liver is enlarged in size (17.8 cm) and shows mild diffuse increase in echotexture. No obvious focal lesion is seen. Intrahepatic biliary radicles not dilated. Hepatic and portal veins are normal. CBD is normal.

GALL BLADDER:

Normal in distension. Lumen echo free. Wall thickness is normal.

PANCREAS:

Head and body visualized appears normal. No focal lesion is seen. Pancreatic duct not dilated. Tail not visualized.

SPLEEN:

Mildly enlarged in size (13.7 cm) with normal echotexture. No focal lesion seen.

RIGHT KIDNEY:

Right kidney measures 11.5 x 1.3 cm (length x parenchymal thickness) with normal echo pattern and cortical thickness.

The shape, size and contour of the right kidney appear normal.

Cortical medullary differentiation is maintained.

No evidence of pelvicalyceal dilatation. No sonologically detectable calculi seen.

LEFT KIDNEY:

Left kidney measures 12.6 x 1.5 cm (length x parenchymal thickness) with normal echo pattern and cortical thickness.

The shape, size and contour of the left kidney appear normal.

Cortical medullary differentiation is maintained.

No evidence of pelvicalyceal dilatation. No sonologically detectable calculi seen.

NAME:	Mr. SRIDHAR	DATE:	28-01-2023
AGE:	34 YEARS	ID. NO:	200877
GENDER:	MALE	REFERRED BY:	OLYMPUS DIAGNOSTICS

USG REPORT - ABDOMEN AND PELVIS

URINARY BLADDER:

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen. Wall thickness appears normal.

PROSTATE:


Is normal in size (Volume-14.1cc) with normal echo pattern. No focal lesion is seen.

No evidence of free fluid in the pelvic or abdominal cavity.

IMPRESSION:

- **Hepatomegaly with grade I fatty changes.**
- **Mild splenomegaly.**

Note: All abnormalities cannot be detected by Ultrasound scan due to technical limitation, obesity and other factors. Scan findings to be correlated with old reports or other investigations.



Dr. MOHAN S. MDRD
Consultant radiologist

ID Card:

Name: MR B SRIDHAR

Age: 34

Weight(Kg): 88

Gender: Male

Height(cm):

BP(mmHg): 126/91

801 Sinus Rhythm
861 PAC-Premature Atrial Contraction
203 Right Axis Deviation
121 Clockwise Rotation
** SUSPECTED ABNORMAL ECG **

P-R: 126 ms

Q-R-S: 113 ms


QT/QTc: 360/413 ms

P/QRS/T AXES: 66/92/66 deg

RV5/SV1: 0.55/0.82 mV

RV5+SV1: 1.37 mV

Report Confirmed by:



10mm/mV AUTO

10mm/mV

25mm/s AC:ON 0.05-35Hz